Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Fig. 1

Violin plots for hemoglobin, white blood cell counts (WBC), and platelets at baseline and upon maximum deterioration (A). Incidence of grade ≥ 3 hematologic adverse events by risk factor: extent of bone tumor burden with 1) none, uni-/oligo-/multifocal (≤ 20) or 2) disseminated and diffuse bone metastases, chemo-naïve or after previous taxane-based chemotherapy, patients previously receiving 223Ra-dichloride or patients with previous hematological decline (CTCAE grade) (B)

Back to article page